Oxalate, Primary Hyperoxaluria, Microbiome Clinical Trial
Official title:
Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients
To characterize the microbiome in 4 groups of subjects (primary hyperoxaluria type I (PH1), idiopathic CaOx stone, enteric hyperoxaluria (EH) and healthy participants) by comparing the number of species and diversity of the microbial populations and pathway for oxalate metabolism by paralleling the gene expression of enzymes involved in oxalate degradation by gut bacteria.
Kidney stones affect as much as 10% of the US population with the most common type of stones
made of calcium oxalate. Calcium and oxalate are present in the urine and can bind to each
other, and form calcium oxalate kidney stones. Oxalate is absorbed in the gut from the food
that is eaten and is removed from the body through urination. Gut bacteria is thought to play
a role in decreasing oxalate absorption in the gut and its levels in the urine. With this
research we hope to learn about differences in the bacteria that live in the gut of different
groups of participants who are likely to form kidney stones, as well as healthy individuals.
We will study healthy people with no history of kidney stones, people with a history of
calcium oxalate (CaOx) kidney stones, people with a genetic disease called primary
hyperoxaluria type1 (PH1) that increases their chances to form calcium oxalate kidney stones
and, people with enteric hyperoxaluria (EH) a disease in which individuals have short bowels
due to surgery which lead them to get calcium oxalate kidney stones.
Our research questions are:
1. How different is the gut bacteria between participants with the conditions that make
them more likely to form kidney stones and healthy participants with no history of
kidney stones?
2. Is there any difference in the function of the individual bacteria, Oxalobacter
formigenes known to reduce oxalate, between healthy participants with no history kidney
stones and participants with PH1?
;